Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batiraxcept + Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT04729608Phase 3Terminated
- Sponsor
- Aravive, Inc.
- Start
- Apr 2021
- Primary completion
- Aug 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 11
01
Overview
A Phase 3 trial of batiraxcept in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Aravive, Inc.. Started Apr 2021; status: terminated.
02
Drugs
batiraxcept
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04729608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729608.